Agent | Bilirubin | Aminotransferases | Percent dose administered | Reference |
Bendamustine | ≥1.5 × ULN | ≥2.5 × ULN | Not recommended | |
Bortezomib | >1.5 × ULN | | Reduce starting dose to 0.7 mg/m2 | |
Cabazitaxel | >ULN | AST/ALT ≥1.5 × ULN | 0% | |
Carfilzomib | | | Refer to text | |
Cyclophosphamide | 3.1 to 5 mg/dL | AST ≥180 IU/L | 75% | [1] |
>5 mg/dL | | 0% |
Cytarabine | | Any | 50%; subsequent increase by monitoring toxicity | [1] |
Dactinomycin | | Any | 50%; subsequent increase by monitoring toxicity | |
Daunorubicin | 1.2 to 3 mg/dL | | 75% | [1] |
3 to 5 mg/dL | | 50% |
>5 mg/dL | | 0% |
Docetaxel | | | Refer to text | |
Doxorubicin | 1.2 to 3 mg/dL | ALT or AST >3 × ULN | 50% | [1] |
3 to 5 mg/dL | | 25% |
>5 mg/dL | | 0% |
Epirubicin | 1.2 to 3 mg/dL | 2 to 4 × ULN | 75% | [1] |
>3 mg/dL | >4 × ULN | 50% |
Eribulin | | | Refer to text | |
Etoposide | 1.5 to 3 mg/dL | AST >3 × ULN | 50% | [1] |
Fluorouracil | >5 mg/dL | | 0% | [1] |
Gemcitabine | >1.6 mg/dL | | 80%¶ | |
Ifosfamide | >3 mg/dL | | 25% | [1,2] |
Irinotecan | 1.5 to 3 mg/dL | | 75% | [1] |
Ixabepilone monotherapy | ≤1 × ULN | AST and ALT ≤2.5 × ULN | Initial dose (40 mg/m2) | |
≤1 × ULN | AST and ALT ≤10 × ULN | Initial dose (32 mg/m2) |
>1.5 to ≤3 × ULN | AST and ALT ≤10 × ULN | Initial dose (20 to 30 mg/m2) |
>3 × ULN | >10 × ULN | Not recommended |
Ixabepilone plus capecitabine | ≥2.5 × ULN | Above ULN | Not recommended | |
Ixazomib | >1.5 × ULN | | Reduce starting dose to 3 mg | |
Paclitaxel | | | Refer to text | |
Panobinostat | ≥1 × ULN | AST >1 × ULN | 75% | |
>1 to 1.5 × ULN | Any | 75% |
>1.5 to 3 × ULN | Any | 50% |
>3 × ULN | | Not recommended |
Pomalidomide | | | Refer to text | |
Procarbazine | >5 mg/dL | ALT or AST >3 × ULN | 0% | [1] |
Trabectedin | | | Refer to text | |
Vincristine, vinblastine | >3 mg/dL | | 50% | [3] |
Vinorelbine | 2.1 to 3 mg/dL | | 50% | [1] |
>3 mg/dL | | 25% |
Vorinostat | >1 to 3 × ULN | | Reduce initial doseΔ | |
>3 × ULN | | Not recommended |